The first registered and meticulously researched, fully human mAB licensed for the treatment of AD was dupilumab, which blocks IL-4Rα—a shared receptor unit for interleukin-4 (IL-4) and interleukin-13 (IL-13) [33]. This evidence concerns the gene IL13 and Alzheimer disease.